Consensus Cipla Limited

Stocks

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 19:05:07 21/10/2026 HKT			5-day change	1st Jan Change
1,314.00 ^INR	-0.76%		-1.17%	-13.05%

10-07	Cipla Health Announces Appointment of Gaurav Kaul as Managing Director, Effective October 2026	CI
09-23	Cipla Limited and Cipla Usa Inc. Announces Management Changes, Effective October 1, 2026	CI

Evolution of the Average Target: Cipla Limited

Evolution of the Target Price: Cipla Limited

Changes in Analyst Recommendations: Cipla Limited

e67680b907d14ebeb8e8db4eed7.-o_jlp-HeraNRQve7DxIvUDKUYcfb1qCer2-oQR7JoY.wvmUxqbEMMHlFUm6wU4kiBenPswmJBu7I4jw4FIkUPKe-Y7U3sEA-P4LPw~b03c9542a411970f49c0dbb9b125230f

Analysts' recommendations: Cipla Limited

07-24	Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform	MT
06-24	Avendus Spark Upgrades Cipla to Buy from Add; Price Target is INR1,710	MT
05-14	Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349	MT
05-14	Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180	MT
05-14	JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546	MT
05-14	Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450	MT
05-14	Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455	MT
05-14	Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404	MT
05-08	Jefferies Adjusts Cipla's Price Target to INR1,120 From INR1,170, Keeps at Underperform	MT
04-24	ICICI Securities Upgrades Cipla to Buy from Add; Price Target is INR1,550	MT
01-27	Nomura Adjusts Cipla's Price Target to INR1,510 From INR1,770, Keeps at Buy	MT
01-26	Jefferies Downgrades Cipla to Underperform From Hold, Adjusts Price Target to INR1,170 From INR1,630	MT
11-03	Nomura Adjusts Cipla's Price Target to INR1,770 From INR1,810, Keeps at Buy	MT
31/10/25	Choice Equity Downgrades Cipla to Add from Buy; Price Target is INR1,700	MT
31/10/25	Choice Equity Downgrades Cipla to Reduce from Add, Price Target is INR1,580	MT
31/10/25	Phillip Securities Upgrades Cipla to Neutral from Sell; Price Target is INR1,420	MT
31/10/25	Prabhudas Lilladher Downgrades Cipla to Accumulate from Buy, Price Target is INR1,675	MT
31/10/25	JM Financial Downgrades Cipla to Reduce from Hold; Price Target is INR1,600	MT
29/07/25	Nomura Adjusts Cipla's Price Target to INR1,810 From INR1,780, Keeps at Buy	MT
14/05/25	Jefferies Adjusts Cipla's Price Target to INR1,610 From INR1,580, Keeps at Hold	MT
31/01/25	Nomura Adjusts Cipla's Price Target to INR1,780 From INR1,800, Keeps at Buy	MT
29/01/25	Jefferies Adjusts Cipla's Price Target to INR1,580 From INR1,560, Keeps at Hold	MT
05/11/24	Nomura Upgrades Cipla to Buy From Neutral, Adjusts Price Target to INR1,800 From INR1,568	MT
30/10/24	Jefferies Adjusts Cipla's Price Target to INR1,480 From INR1,450, Keeps at Hold	MT
29/07/24	Jefferies Adjusts Cipla's Price Target to INR1,450 From INR1,400, Keeps at Hold	MT

More recommendations

Generic Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CIPLA LIMITED					+14.21%
	ELI LILLY AND COMPANY					+3.71%
	JOHNSON & JOHNSON					+7.73%
	ABBVIE INC.					-2.24%
	ROCHE HOLDING AG					-1.52%
	MERCK & CO., INC.					+6.92%
	NOVARTIS AG					-2.21%
	ASTRAZENECA PLC					+24.46%
	AMGEN INC.					-10.02%
	GILEAD SCIENCES, INC.					+2.33%
	Average					+4.34%
	Weighted average by Cap.					+3.46%